IL254159A0 - Tripulse release stimulant formulations - Google Patents
Tripulse release stimulant formulationsInfo
- Publication number
- IL254159A0 IL254159A0 IL254159A IL25415917A IL254159A0 IL 254159 A0 IL254159 A0 IL 254159A0 IL 254159 A IL254159 A IL 254159A IL 25415917 A IL25415917 A IL 25415917A IL 254159 A0 IL254159 A0 IL 254159A0
- Authority
- IL
- Israel
- Prior art keywords
- tripulse
- release stimulant
- formulations
- stimulant formulations
- release
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121537P | 2015-02-27 | 2015-02-27 | |
| PCT/US2016/019877 WO2016138440A1 (en) | 2015-02-27 | 2016-02-26 | Tripulse release stimulant formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL254159A0 true IL254159A0 (en) | 2017-10-31 |
| IL254159B IL254159B (en) | 2022-10-01 |
| IL254159B2 IL254159B2 (en) | 2023-02-01 |
Family
ID=56789928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL254159A IL254159B2 (en) | 2015-02-27 | 2017-08-27 | Tripulse release stimulant formulations |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20160250148A1 (en) |
| EP (1) | EP3261625A4 (en) |
| JP (2) | JP2018506590A (en) |
| KR (2) | KR20240001281A (en) |
| CN (1) | CN107530289A (en) |
| AU (2) | AU2016225052B2 (en) |
| BR (1) | BR112017018322A2 (en) |
| CA (1) | CA2977540C (en) |
| HK (1) | HK1248102A1 (en) |
| IL (1) | IL254159B2 (en) |
| MX (1) | MX2017011005A (en) |
| WO (1) | WO2016138440A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021197376A1 (en) * | 2020-03-31 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | A febuxostat tablet |
| WO2022240849A1 (en) * | 2021-05-11 | 2022-11-17 | Cingulate Therapeutics LLC | Trimodal, precision-timed pulsatile release tablet |
| WO2023158694A1 (en) * | 2022-02-16 | 2023-08-24 | Cingulate Therapeutics LLC | Trimodal, precision-timed release tablet |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3131402A1 (en) | 1981-08-07 | 1983-02-24 | Kilian & Co GmbH, 5000 Köln | METHOD AND TABLET PRESS FOR THE SUCCESSFUL PRODUCTION OF A VARIETY OF TABLETS OF THE SAME WEIGHT |
| DE3404108A1 (en) | 1984-02-07 | 1985-08-14 | Kilian & Co GmbH, 5000 Köln | TABLET PRESS |
| DE9306785U1 (en) | 1993-05-05 | 1993-07-08 | Kilian & Co. Gmbh Maschinenfabrik, 5000 Koeln, De | |
| ES2178078T3 (en) | 1997-07-23 | 2002-12-16 | Kilian Gmbh & Co Kg | PRESS OF TABLETS WITH CONCENTRAL MARCH. |
| US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
| CA2366791A1 (en) * | 1999-04-06 | 2000-10-12 | Kamal K. Midha | Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant |
| US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
| MXPA02012640A (en) | 2000-06-20 | 2004-09-10 | Sanwa Kagaku Kenkyusho Co | Nucleated molded article, method of producing the same, and device for producing the same. |
| AU2001268722B8 (en) * | 2000-06-23 | 2005-09-29 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| ATE418956T1 (en) | 2001-09-26 | 2009-01-15 | Sanwa Kagaku Kenkyusho Co | METHOD AND APPARATUS FOR PRODUCING A MULTI-CORE MOLDED ARTICLE |
| JP4248225B2 (en) | 2002-11-01 | 2009-04-02 | トヨタ自動車株式会社 | Fuel cell system |
| ES2618781T3 (en) | 2003-11-14 | 2017-06-22 | Sanwa Kagaku Kenkyusho Co., Ltd. | Manufacturing procedure of a nucleated molding |
| KR101172926B1 (en) | 2004-08-26 | 2012-08-10 | 가부시키가이샤산와카가쿠켄큐쇼 | Mallet and rotary compression forming machine using the same |
| DE202005001556U1 (en) | 2005-01-31 | 2006-03-16 | Kilian Gmbh & Co. Kg | Matritzenscheibe for rotary tablet press and rotary tablet press |
| EP2023900B1 (en) * | 2006-05-12 | 2014-12-24 | Shire LLC | Controlled dose drug delivery system |
| CA2678806C (en) * | 2007-02-21 | 2017-05-16 | Connected Health Systems, Llc | Treating adhd and other diseases involving inflammation |
| DE202007002707U1 (en) | 2007-02-21 | 2008-07-03 | Ima Kilian Gmbh & Co.Kg | Fill shoe for rotary tablet presses |
| CA2694602A1 (en) * | 2007-07-27 | 2009-02-05 | Depomed, Inc. | Pulsatile gastric retentive dosage forms |
| CA2742680C (en) * | 2008-11-07 | 2013-12-31 | Samyang Corporation | Pharmaceutical compositions for release control of methylphenidate |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| CA3018328A1 (en) * | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
-
2016
- 2016-02-26 AU AU2016225052A patent/AU2016225052B2/en active Active
- 2016-02-26 JP JP2017563509A patent/JP2018506590A/en active Pending
- 2016-02-26 BR BR112017018322A patent/BR112017018322A2/en not_active Application Discontinuation
- 2016-02-26 CN CN201680012546.6A patent/CN107530289A/en active Pending
- 2016-02-26 US US15/054,934 patent/US20160250148A1/en not_active Abandoned
- 2016-02-26 KR KR1020237043973A patent/KR20240001281A/en not_active Application Discontinuation
- 2016-02-26 CA CA2977540A patent/CA2977540C/en active Active
- 2016-02-26 WO PCT/US2016/019877 patent/WO2016138440A1/en active Application Filing
- 2016-02-26 MX MX2017011005A patent/MX2017011005A/en unknown
- 2016-02-26 KR KR1020177027388A patent/KR20170134409A/en active Application Filing
- 2016-02-26 EP EP16756485.5A patent/EP3261625A4/en active Pending
-
2017
- 2017-08-27 IL IL254159A patent/IL254159B2/en unknown
- 2017-12-22 US US15/852,168 patent/US20180185290A1/en not_active Abandoned
-
2018
- 2018-06-08 HK HK18107473.1A patent/HK1248102A1/en unknown
-
2019
- 2019-11-12 US US16/681,261 patent/US20200146991A1/en not_active Abandoned
-
2020
- 2020-09-11 JP JP2020153173A patent/JP2021001190A/en active Pending
-
2021
- 2021-10-07 AU AU2021245179A patent/AU2021245179B2/en active Active
-
2022
- 2022-08-25 US US17/822,226 patent/US20230121531A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021245179B2 (en) | 2024-03-07 |
| WO2016138440A1 (en) | 2016-09-01 |
| BR112017018322A2 (en) | 2018-04-17 |
| CA2977540C (en) | 2023-10-03 |
| AU2016225052B2 (en) | 2021-07-08 |
| EP3261625A4 (en) | 2018-10-24 |
| AU2021245179A1 (en) | 2021-11-04 |
| EP3261625A1 (en) | 2018-01-03 |
| KR20240001281A (en) | 2024-01-03 |
| AU2016225052A1 (en) | 2017-09-21 |
| MX2017011005A (en) | 2018-01-16 |
| CA2977540A1 (en) | 2016-09-01 |
| IL254159B2 (en) | 2023-02-01 |
| US20180185290A1 (en) | 2018-07-05 |
| KR20170134409A (en) | 2017-12-06 |
| US20200146991A1 (en) | 2020-05-14 |
| US20230121531A1 (en) | 2023-04-20 |
| IL254159B (en) | 2022-10-01 |
| CN107530289A (en) | 2018-01-02 |
| US20160250148A1 (en) | 2016-09-01 |
| HK1248102A1 (en) | 2018-10-12 |
| JP2021001190A (en) | 2021-01-07 |
| JP2018506590A (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268697A (en) | Formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL265609A (en) | Novel formulations | |
| GB201607918D0 (en) | Novel formulations | |
| HK1258718A1 (en) | Controlled-release formulations | |
| IL254132A0 (en) | Solid preparation | |
| ZA201704263B (en) | Controlled-release formulations | |
| GB201419261D0 (en) | Formulations | |
| GB201419091D0 (en) | Formulations | |
| IL275735A (en) | Sustained release olanzapine formulations | |
| HK1248102A1 (en) | Tripulse release stimulant formulations | |
| HK1252549A1 (en) | Controlled-release tozadenant formulations | |
| IL252955B (en) | Mouthrinse formulations | |
| GB201520724D0 (en) | Veterinary formulations | |
| GB201805338D0 (en) | Cosmetic formulations | |
| IL268195A (en) | Solid fosmetpantothenate formulations | |
| GB201621277D0 (en) | Formulations | |
| GB201714461D0 (en) | Formulations | |
| GB201618110D0 (en) | Formulations | |
| GB201616366D0 (en) | Formulations | |
| GB201615754D0 (en) | Formulations | |
| ZA201703472B (en) | Mouthrinse formulations | |
| GB201617866D0 (en) | Novel formulations | |
| GB201616509D0 (en) | Novel formulations | |
| GB201507784D0 (en) | Formulations |